Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.89 Average Price Target from Analysts

Key Points

• Immunocore Holdings PLC has received a consensus rating of "Hold" from 11 ratings firms, with one sell, four hold, and six buy ratings.
• The company's stock is currently trading at approximately $36.57, with an average 1-year price target set by analysts at $56.89.
• Institutional investors hold 84.5% of Immunocore's shares, with notable increases in holdings from several firms during the second quarter.

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) have been given a consensus rating of "Hold" by the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $56.8889.

IMCR has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Immunocore in a research report on Tuesday, May 27th. They set a "buy" rating and a $65.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Immunocore in a research report on Monday, June 2nd. Zacks Research downgraded Immunocore from a "strong-buy" rating to a "hold" rating in a research report on Thursday, September 4th. Jefferies Financial Group initiated coverage on Immunocore in a research report on Monday, August 25th. They set a "buy" rating and a $48.00 price target for the company. Finally, Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th.

Immunocore Stock Down 1.2%

Shares of IMCR stock traded down $0.39 during trading hours on Friday, reaching $33.42. The company had a trading volume of 553,886 shares, compared to its average volume of 267,557. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -83.55 and a beta of 0.77. The business has a fifty day simple moving average of $34.02 and a 200-day simple moving average of $31.85. Immunocore has a 12 month low of $23.15 and a 12 month high of $39.33.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The company had revenue of $130.65 million during the quarter, compared to the consensus estimate of $122.96 million. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.Immunocore's revenue was up 30.0% on a year-over-year basis. During the same period last year, the business posted ($0.23) earnings per share. On average, research analysts expect that Immunocore will post -0.94 earnings per share for the current fiscal year.

Insider Activity

In other Immunocore news, insider David M. Berman sold 22,532 shares of the business's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by insiders.

Institutional Trading of Immunocore

Several hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. raised its stake in shares of Immunocore by 117.4% in the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company's stock valued at $97,000 after buying an additional 1,700 shares during the period. Orion Porfolio Solutions LLC raised its stake in shares of Immunocore by 4.5% in the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company's stock valued at $752,000 after buying an additional 1,031 shares during the period. State of Tennessee Department of Treasury bought a new stake in shares of Immunocore in the second quarter valued at $132,000. Oxford Asset Management LLP bought a new stake in shares of Immunocore in the second quarter valued at $661,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Immunocore in the second quarter valued at $2,789,000. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.